Scott R. Plotkin

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Tracy T. Batchelor, A. Gregory Sorensen, Emmanuelle di Tomaso et al. · Cancer Cell · 2007 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation

Eric Legius, Ludwine Messiaen, P. Wolkenstein et al. · Genetics in Medicine · 2021 · 771 citations · Full text

Medicine, Dermatology, Ophthalmology +14

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

Scott R. Plotkin, Anat Stemmer‐Rachamimov, Fred G. Barker et al. · New England Journal of Medicine · 2009 · 529 citations · Full text

Medicine, Oncology, Otolaryngology +16

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

Tracy T. Batchelor, Dan G. Duda, Emmanuelle di Tomaso et al. · Journal of Clinical Oncology · 2010 · 516 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

David A. Reardon, Karen Fink, Tom Mikkelsen et al. · Journal of Clinical Oncology · 2008 · 473 citations · Full text

Medicine, Oncology, Pharmacology +16